1. Remdesivir therapy in patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials
- Author
-
John M. Pederson, Nitin Gupta, Kevin M. Kallmes, Amber R. Davis, Kirk W. Evanson, Charan Thej Reddy Vegivinti, Averi Barrett, and Kavitha Saravu
- Subjects
medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,medicine.medical_treatment ,SARS virus ,Review Article ,law.invention ,Odds ,03 medical and health sciences ,0302 clinical medicine ,Randomized controlled trial ,law ,Internal medicine ,Hospital discharge ,medicine ,Extracorporeal membrane oxygenation ,In patient ,Mechanical ventilation ,business.industry ,Therapeutic uses ,General Medicine ,Coronavirus ,Antiviral agents ,030220 oncology & carcinogenesis ,Meta-analysis ,030211 gastroenterology & hepatology ,Surgery ,business - Abstract
Purpose To perform a systematic review and meta-analysis of randomized controlled trials that examined remdesivir treatment for COVID-19. Materials and methods A systematic literature search was performed using Pubmed, Embase, and ClinicalTrials.gov to identify studies published up to October 25, 2020 that examined COVID-19 treatment with remdesivir. A total of 3 randomized controlled trials that consisted of 1691 patients were included in the meta-analysis. Results The odds for mechanical ventilation (MV) or extracorporeal membrane oxygenation (ECMO) following treatment was significantly lower in the remdesivir group compared to the control group (OR = 0.48 [95% CI: 0.34; 0.69], p, Highlights • Remdesivir reduces the odds for mechanical ventilation or extracorporeal membrane oxygenation in COVID-19 patients. • Remdesivir improves the odds for hospital discharge. • Remdesivir does not lower the odds for mortality. • Remdesivir can attenuate COVID-19 progression, but it is less effective in treating critically-ill patients.
- Published
- 2021